Which statement is true about MRD and imaging?

Which statement is true about MRD and imaging?

• A. MRD testing is more sensitive than imaging
• B. Imaging is more sensitive than MRD
• C. MRD and imaging have identical sensitivity
• D. MRD is not used for recurrence detection

Answer: (A)

The main idea here is how sensitive different methods are at spotting cancer when it’s very small or just beginning to come back. MRD testing detects cancer at the cellular or molecular level, far below what imaging can reveal. It uses techniques like flow cytometry, PCR, or next-generation sequencing to find one cancer cell among tens of thousands or even a million normal cells. Imaging, on the other hand, looks for visible masses or metabolic activity above certain thresholds, which means very small or dispersed disease can be missed. Because MRD can pick up tiny amounts of disease long before it forms a visible lesion, it often detects relapse earlier and with greater sensitivity than imaging. This is especially true in blood cancers like leukemias and lymphomas, where MRD status provides strong prognostic information. Of course, imaging remains important for locating disease and assessing anatomical spread, especially in solid tumors, but the sensitivity advantage of MRD for detecting minimal disease makes the statement true: MRD testing is more sensitive than imaging.

The main idea here is how sensitive different methods are at spotting cancer when it’s very small or just beginning to come back. MRD testing detects cancer at the cellular or molecular level, far below what imaging can reveal. It uses techniques like flow cytometry, PCR, or next-generation sequencing to find one cancer cell among tens of thousands or even a million normal cells. Imaging, on the other hand, looks for visible masses or metabolic activity above certain thresholds, which means very small or dispersed disease can be missed.

Because MRD can pick up tiny amounts of disease long before it forms a visible lesion, it often detects relapse earlier and with greater sensitivity than imaging. This is especially true in blood cancers like leukemias and lymphomas, where MRD status provides strong prognostic information. Of course, imaging remains important for locating disease and assessing anatomical spread, especially in solid tumors, but the sensitivity advantage of MRD for detecting minimal disease makes the statement true: MRD testing is more sensitive than imaging.